YM BioSciences public offering raises $80.5m
This article was originally published in Scrip
Executive Summary
YM Biosciences, a Canadian drug development company, has raised $80.5 million in its recent public offering, in one of the largest Canadian biotech offerings in recent years. The money will be used to fund development of CYT386, YM's Phase I/II JAK1/JAK2 inhibitor to treat myelofibrosis.